Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment

Author(s):
Sliz, E.; Kettunen, J.; Holmes, M.V.; Williams, C.O.; Boachie, C.; Wang, Q.; Mannikko, M.; Sebert, S.; Walters, R.; Lin, K.; Millwood, I.Y.; Clarke, R.; Li, L.; Rankin, N.; Welsh, P.; Delles, C.; Jukema, J.W. (0000-0002-3246-8359); Trompet, S.; Ford, I.; Perola, M.; Salomaa, V.; Jarvelin, M.R.; Chen, Z.; Lawlor, D.A.; Ala-Korpela, M.; Danesh, J.; Davey Smith, G.; Sattar, N.; Butterworth, A.; Wurtz, P.
Published
2018
Publication type
Article / Letter to editor
lipoproteinsMendelian randomization analysismetabolomicsstatins
Date issued
2018-11-27
Language
English
Is part of
Circulation (2018), Vol. 138, no. 22, p. 2499-2512
hdl
1887/86683
doi
10.1161/CIRCULATIONAHA.118.034942
URL
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254781/?report=classic